Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.
Saved in:
| Title: | Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. |
|---|---|
| Authors: | Bye AP; Molecular and Clinical Sciences Research Institute, St George's University, Cranmer Terrace, London, United Kingdom; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX. a.bye@sgul.ac.uk., Kriek N; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX., Sage T; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX., Rawlings SJ; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading,., Prodger C; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE., Kesavan M; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE., Lees C; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE., Booth S; Department of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, RG1 5AN., Cowen LG; Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE., Shefferd K; Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE., Desborough MJ; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE., Gibbins JM; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX., Eyre TA; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,. |
| Source: | Haematologica [Haematologica] 2023 May 01; Vol. 108 (5), pp. 1429-1435. Date of Electronic Publication: 2023 May 01. |
| Publication Type: | Letter; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36519322 AccessLevel: 2 PubType: Report PubTypeId: report PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bye+AP%22">Bye AP</searchLink>; Molecular and Clinical Sciences Research Institute, St George's University, Cranmer Terrace, London, United Kingdom; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX. a.bye@sgul.ac.uk.<br /><searchLink fieldCode="AU" term="%22Kriek+N%22">Kriek N</searchLink>; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.<br /><searchLink fieldCode="AU" term="%22Sage+T%22">Sage T</searchLink>; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.<br /><searchLink fieldCode="AU" term="%22Rawlings+SJ%22">Rawlings SJ</searchLink>; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading,.<br /><searchLink fieldCode="AU" term="%22Prodger+C%22">Prodger C</searchLink>; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.<br /><searchLink fieldCode="AU" term="%22Kesavan+M%22">Kesavan M</searchLink>; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.<br /><searchLink fieldCode="AU" term="%22Lees+C%22">Lees C</searchLink>; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.<br /><searchLink fieldCode="AU" term="%22Booth+S%22">Booth S</searchLink>; Department of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, RG1 5AN.<br /><searchLink fieldCode="AU" term="%22Cowen+LG%22">Cowen LG</searchLink>; Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.<br /><searchLink fieldCode="AU" term="%22Shefferd+K%22">Shefferd K</searchLink>; Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.<br /><searchLink fieldCode="AU" term="%22Desborough+MJ%22">Desborough MJ</searchLink>; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE.<br /><searchLink fieldCode="AU" term="%22Gibbins+JM%22">Gibbins JM</searchLink>; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.<br /><searchLink fieldCode="AU" term="%22Eyre+TA%22">Eyre TA</searchLink>; Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220417435%22">Haematologica</searchLink> [Haematologica] 2023 May 01; Vol. 108 (5), pp. 1429-1435. <i>Date of Electronic Publication: </i>2023 May 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Letter; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Ferrata+Storti+Foundation%22">Ferrata Storti Foundation </searchLink><i>Country of Publication: </i>Italy <i>NLM ID: </i>0417435 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1592-8721 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203906078%22">03906078 </searchLink><i>NLM ISO Abbreviation: </i>Haematologica <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36519322 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3324/haematol.2022.281402 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1429 Titles: – TitleFull: Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bye AP – PersonEntity: Name: NameFull: Kriek N – PersonEntity: Name: NameFull: Sage T – PersonEntity: Name: NameFull: Rawlings SJ – PersonEntity: Name: NameFull: Prodger C – PersonEntity: Name: NameFull: Kesavan M – PersonEntity: Name: NameFull: Lees C – PersonEntity: Name: NameFull: Booth S – PersonEntity: Name: NameFull: Cowen LG – PersonEntity: Name: NameFull: Shefferd K – PersonEntity: Name: NameFull: Desborough MJ – PersonEntity: Name: NameFull: Gibbins JM – PersonEntity: Name: NameFull: Eyre TA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2023 May 01 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1592-8721 Numbering: – Type: volume Value: 108 – Type: issue Value: 5 Titles: – TitleFull: Haematologica Type: main |
| ResultId | 1 |
